TORONTO, Ont. (PRWEB) November 4, 2005 –-
Euoko, Inc., a pioneer of zero-compromise, prestige skin treatments has introduced in its exclusive Louvre Collection a new synthetic tripeptide that mimics the activity of Waglerin-1, a protein found in the venom of the Temple Viper, Tropidolaemus wagleri. This safe tripeptide, developed in Switzerland, has been clinically shown to reduce the size, depth and number of wrinkles – particularly expression lines – by relaxing facial muscles, in a way similar to medical injections, but without the risk, the expense or the inconvenience.
Six times more effective than the leading competitive product, this new tripeptide has shown the ability to reduce forehead wrinkles by 52% and crow’s feet by 38% in 28 days or less. Euoko’s Louvre Collection combines this tripeptide with a host of such well-trusted ingredients as Antarticine, APT, Argireline, MDI Complex, Aldenine, Pepha Tight, EUK 134 (a superior antioxidant to the ever famous Superoxide Dismutase) and a unique, superior Hyaluronic Acid from Denmark that is biotechnologically produced without the involvement of Strepp bacteria. Third-party clinical studies that stand behind every one of these ingredients are documented and available upon request.
The Louvre Collection is one of Euoko’s five clinically-proven treatment collections offered for various skin conditions from lines, wrinkles and cellulite to under-eye dark circles and pigmentation irregularities. Detailed information about Euoko’s superb collection and ingredients can be found at http://www.euoko.com.
About Euoko, Inc.
Euoko, Inc. is a manufacturer and distributor of the most exclusive luxury skin care treatments that incorporate the leading-edge developments in technology and formulation. Headquartered in Canada, Euoko is rapidly expanding across North America and Europe with recent sales office additions in Toronto, San Diego, London and Milan.
Telephone: 1-800-98-EUOKO (38656)
Fax: 1-800-97-EUOKO (38656)